Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Cardiovascular Diseases D002318 24 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Central Nervous System Diseases D002493 10 associated lipids
Brain Ischemia D002545 89 associated lipids
Ischemic Attack, Transient D002546 42 associated lipids
Cerebrovascular Disorders D002561 25 associated lipids
Cholecystitis D002764 8 associated lipids
Cholestasis D002779 23 associated lipids
Cholestasis, Intrahepatic D002780 4 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Cluster Headache D003027 4 associated lipids
Colitis D003092 69 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Colonic Diseases D003108 5 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Conjunctivitis D003231 7 associated lipids
Constriction, Pathologic D003251 8 associated lipids
Contracture D003286 3 associated lipids
Coronary Artery Disease D003324 47 associated lipids
Coronary Disease D003327 70 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Goldie RG et al. PAF receptors in guinea-pig and human lung. 1990 Agents Actions Suppl. pmid:1964365
Alabaster VA et al. UK-74,505, a novel and selective PAF antagonist, exhibits potent and long lasting activity in vivo. 1991 Agents Actions Suppl. pmid:1793066
Heuer HO The effects of hetrazepine PAF antagonists in preclinical models of asthma. 1991 Agents Actions Suppl. pmid:1793067
Mazzoni L et al. Changes in airway sensitivity to histamine are not necessarily paralleled by changed sensitivity to acetylcholine. 1991 Agents Actions Suppl. pmid:1793069
Hoshiko K et al. Histamine(H1) antagonists and airway hyperreactivity in the guinea-pig. 1991 Agents Actions Suppl. pmid:1686527
Mest HJ et al. Effect of BN 52256 and other mediator antagonists on ouabain-induced ventricular fibrillation in sensitized guinea-pigs and on ischemia-induced fibrillation in rats. 1992 Agents Actions Suppl. pmid:1632298
Koltai M and Braquet PG Involvement of PAF in atherogenesis. Brief review. 1992 Agents Actions Suppl. pmid:1632308
McMillan RM and Carter GW Design and development of drugs. 1991 Agents Actions Suppl. pmid:1664186
Rihoux JP The inhibiting effect of cetirizine 2 HC1 on eosinophil migration and its link to H1 blockade. 1991 Agents Actions Suppl. pmid:1675836
Kurosawa M Effect of platelet activating factor on histamine release from rat mast cells. 1987 Agents Actions Suppl. pmid:2445185
Page CP and Spina D The therapeutic relevance of PAF antagonists. 1989 Agents Actions Suppl. pmid:2683635
Rink TJ Stimulus-response coupling mechanisms in human platelets. 1986 Agents Actions Suppl. pmid:3028101
Baroggi N et al. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds. 1986 Agents Actions Suppl. pmid:3028108
Page CP et al. Drugs affecting pulmonary responses to platelet activating factor as novel anti-asthma drugs. 1988 Agents Actions Suppl. pmid:3051932
Muirhead EE Vasodepressor lipid of the renomedullary interstitial cells of the renal papilla is a prohormone activated by the liver. 1987 Agents Actions Suppl. pmid:3324720
Szczeklik A et al. Bleeding time and PAF-acether-induced platelet aggregation in atopy. 1987 Agents Actions Suppl. pmid:3478996
Schmitz-Schumann M et al. Evidence of PAF release and platelet activation in analgesics-asthma-syndrome. 1987 Agents Actions Suppl. pmid:3478999
Guinot P et al. Effects of BN 52063 on PAF-acether induced weal and flare in man. 1987 Agents Actions Suppl. pmid:3479000
Lang M et al. Effects of the PAF-antagonist CV-3988 on PAF-induced changes in mucus secretion and in respiratory and circulatory variables in ferrets. 1987 Agents Actions Suppl. pmid:3479001
Codde JP et al. Effects of altered prostanoid and lyso-PAF synthesis by marine oil diets on blood pressure of salt loaded spontaneously hypertensive rats. 1987 Agents Actions Suppl. pmid:3481207
Morley J PAF and airway hyperreactivity; prospects for novel prophylactic anti-asthma drugs. 1987 Agents Actions Suppl. pmid:3314417
Braquet P et al. The role of PAF-acether in anaphylaxis demonstrated with the use of the antagonist BN 52021. 1987 Agents Actions Suppl. pmid:3314418
Morley J et al. Pharmacological evaluation of prophylactic anti-asthma drugs by reference to the pathological sequelae of exposure to allergen or platelet activating factor. 1988 Agents Actions Suppl. pmid:3262989
Subissi A and Criscuoli M Effects of LG 30435 on different platelet activating factor-induced responses. 1988 Agents Actions Suppl. pmid:3262990
Heuer H and Casals-Stenzel J Effect of the PAF-antagonist WEB 2086 on anaphylactic lung reaction: comparison of inhalative and intravenous challenge. 1988 Agents Actions Suppl. pmid:3262991
König W et al. On the biological role of lipid chemotactic factors. 1983 Agents Actions Suppl. pmid:6404145
Parnham MJ et al. Regulation of the oxidative burst of macrophages by lipid mediators. 1984 Agents Actions Suppl. pmid:6433680
Vargaftig BB Phospholipids, particularly platelet-activating factor (PAF-acether), in experimental bronchoconstriction. 1983 Agents Actions Suppl. pmid:6575594
Page CP et al. PAF-acether: a putative mediator of asthma and inflammation. 1983 Agents Actions Suppl. pmid:6575595
Northover AM Modification by some antagonists of the shape changes of venous endothelial cells in response to inflammatory agents in vitro. 1990 Agents Actions pmid:2111079
McLeod J et al. Effect of 12-O-tetradecanoylphorbol-13-acetate (TPA) on substance P-induced histamine release from rat peritoneal mast cells. 1990 Agents Actions pmid:1695435
Adolfs MJ et al. PAF-acether modifies human peritoneal macrophage cAMP levels in a biphasic fashion. 1989 Agents Actions pmid:2540635
Neumann M and Kownatzki E The effect of adherence on the generation of reactive oxygen species by human neutrophilic granulocytes. 1989 Agents Actions pmid:2540640
Trebien HA and Calixto JB Pharmacological evaluation of rat paw oedema induced by Bothrops jararaca venom. 1989 Agents Actions pmid:2660497
Bekemeier H and Sänze JU Vasodepression ex vivo after administration of inflammatory mediators in vivo in the rat. 1989 Agents Actions pmid:2476918
Jouquey S et al. Comparison of the effects of the ace inhibitors trandolapril and enalapril on phlogogen induced foot pad oedema in the rat. 1988 Agents Actions pmid:2459935
Sanchez Crespo M and Nieto ML Modulation of PAF biosynthesis in human polymorphonuclear leukocytes. The role of phorbol esters and protein kinases. 1989 Agents Actions pmid:2711927
Zijlstra FJ et al. The effects of PAF-acether and FMLP on eicosanoid production in guinea pig alveolar macrophages. 1989 Agents Actions pmid:2711928
Nijkamp FP et al. Role of platelet activating factor in the endotoxin induced tracheal hyperreactivity to histamine in the guinea pig. 1989 Agents Actions pmid:2711929
Oliver JL et al. Effect of PAF acether on oriented egg phosphatidylcholine multibilayers; interaction with cholesterol; comparison to lyso-PC and lyso-PAF. 1989 Agents Actions pmid:2711930
Doyle SA et al. Further studies on the antinociceptive effects of delta 6-THC-7-oic acid. 1990 Agents Actions pmid:2178317
Nieminen MM et al. Body temperature modulates the effect of platelet-activating factor (PAF) on airways responsiveness in the rabbit. 1991 Agents Actions pmid:1862740
Jenei B et al. Hypotensive action of IgG preparations containing aggregates is suppressed by PAF-receptor antagonist BN 52021 and by gadolinium chloride (an agent blocking Kupffer cell function). 1991 Agents Actions pmid:1862750
Kantar A et al. Effect of PAF on erythrocyte membrane heterogeneity: a fluorescence study. 1991 Agents Actions pmid:1862752
Adnot S et al. Antagonists of PAF-acether do not suppress thrombin-induced aggregation of ADP-deprived and aspirin-treated human platelets. 1987 Agents Actions pmid:3115070
Montrucchio G et al. The pattern of cardiovascular alterations induced by infusion of platelet-activating factor in rabbit is modified by pretreatment with H1-H2 receptor antagonists but not by cyclooxygenase inhibition. 1987 Agents Actions pmid:3115072
Carlson RP et al. Pharmacologic modulation of PAF-induced mortality in mice. 1987 Agents Actions pmid:3120513
Anderson GP et al. Increased airways responsiveness to histamine induced by platelet activating factor in the guinea-pig: possible role of lipoxygenase metabolites. 1988 Agents Actions pmid:3136622
Morley J Platelet activating factor and asthma. 1986 Agents Actions pmid:3099555
Cunha FQ et al. Failure of PAF-acether to induce in vivo neutrophil migration. 1988 Agents Actions pmid:3055873
Ramesha CS et al. Identification and quantitation of PAF from psoriatic scales. 1987 Agents Actions pmid:3687590
Friedlander G et al. Renal effects of platelet-activating factor in the rat. 1987 Agents Actions pmid:3687594
Lauri D et al. Contribution of ADP to the amplification of primary platelet aggregation by platelet activating factor (PAF): modulatory role of aspirin. 1986 Agents Actions pmid:3706054
Taira M et al. Lack of involvement of leukotriene and platelet activating factor in passive cutaneous anaphylaxis in rats. 1988 Agents Actions pmid:3407549
Mastacchi R et al. Interaction of a new low molecular weight heparin (OP/LMWH) with human platelets. 1986 Agents Actions pmid:3518359
Kusner EJ et al. Pharmacologic analysis of 1-0-alkyl-2-acetyl-sn-glycero-3-phosphocholine-induced increases in cutaneous vascular permeability in the rat. 1987 Agents Actions pmid:3577957
Archer CB et al. Actions of disodium cromoglycate (DSCG) on human skin responses to histamine, codeine and Paf-acether. 1985 Agents Actions pmid:3923788
Pirotzky E et al. Vascular permeability induced by Paf-acether (platelet-activating factor) in the isolated perfused rat kidney. 1985 Agents Actions pmid:4003192
Page CP et al. Platelet activating factor (Paf-acether) may account for late-onset reactions to allergen inhalation. 1985 Agents Actions pmid:4003195
Page CP et al. Suppression of Paf-acether responses: an anti-inflammatory effect of anti-asthma drugs. 1985 Agents Actions pmid:4003196
Spicer BA et al. An investigation of the involvement of platelet activating factor in the non-histamine immediate hypersensitivity reaction in the rat peritoneal cavity. 1985 Agents Actions pmid:4003197
Boughton-Smith NK et al. Actions of nitric oxide on the acute gastrointestinal damage induced by PAF in the rat. 1992 Agents Actions pmid:1279960
Perales J et al. Neutralization of the oedematogenic activity of Bothrops jararaca venom on the mouse paw by an antibothropic fraction isolated from opossum (Didelphis marsupialis) serum. 1992 Agents Actions pmid:1295374
Wong CW et al. Comparative effects of tetrandrine and berbamine on subcutaneous air pouch inflammation induced by interleukin-1, tumour necrosis factor and platelet-activating factor. 1992 Agents Actions pmid:1414679
Tran A et al. Separate induction of human blood platelet aggregation or cytotoxicity by different concentrations of PAF-acether and thrombin. 1992 Agents Actions pmid:1414687
Northover AM In vitro effects of PAF on venous endothelial cell actin disposition. 1992 Agents Actions pmid:1509977
Okamoto H et al. Suppression of the Arthus reaction by Y-24180, a potent and specific antagonist of platelet-activating factor. 1992 Agents Actions pmid:1388318
Miyagawa H et al. The effect of WEB 2086 on PAF-induced eosinophil chemotaxis and LTC4 production from eosinophils. 1992 Agents Actions pmid:1456179
Lewis AJ et al. The effects of antiallergic and bronchodilator drugs on platelet-activating factor (PAF-acether) induced bronchospasm and platelet aggregation. 1984 Agents Actions pmid:6152379
Benveniste J Platelet-activating factor (PAF-acether): present status. 1981 Agents Actions pmid:6176101
Northover AM and Northover BJ Lectin-induced increase in microvascular permeability to colloidal carbon in vitro may involve protein kinase C activation. 1994 Agents Actions pmid:7942320
Tubaro E et al. In vitro and in vivo impact of a new glycosphingolipid on neutrophils. 1994 Agents Actions pmid:7879694
Canale P et al. TCV-309, a novel platelet activating factor antagonist, inhibits leukocyte accumulation and protects against splanchnic artery occlusion shock. 1994 Agents Actions pmid:7879698
Raff GW et al. Procoagulant property of platelet activating factor (PAF). 1993 Agents Actions pmid:8273543
Meats JE et al. Identification of phospholipase D (PLD) activity in mouse peritoneal macrophages. 1993 Agents Actions pmid:8273553
Thomas TK et al. Differential antagonism of platelet activating factor-induced neutrophilia and gastric hemorrhage in the rat. 1993 Agents Actions pmid:8273566
Glaser KB et al. Pharmacological characterization of WAY-121,520: a potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2). 1993 Agents Actions pmid:8273577
Kantar A et al. Effect of PAF on human lymphocyte membranes: a fluorescence study. 1993 Agents Actions pmid:8317302
Boonen GJ et al. Activation of neutrophil migration by dioctanoyl-sn-glycerol and fMet-Leu-Phe is controlled by different pathways. 1993 Agents Actions pmid:8317308
Murphy G Report of the 14th meeting of the British Inflammation Research Association. Topic: cellular and molecular aspects of inflammatory bowel disease. 1993 Agents Actions pmid:8480529
Perret BA et al. Binding of bovine factor VIII-coated colloidal gold particles to receptors on platelet membranes. 1981 Agents Actions pmid:6803540
Denburg JA et al. Platelet activating factor: regulation by mast cells and aspirin. 1984 Agents Actions pmid:6711391
Lecrubier C et al. Study of platelet aggregation induced by platelet activating factor (PAF) after administration of ticlopidine or aspirin. 1983 Agents Actions pmid:6858789
Jouvin-Marche E et al. Platelet-activating factor (PAF-acether), an activator of neutrophil functions. 1982 Agents Actions pmid:6299078
Caillard CG et al. Hypotensive activity of PAF-acether in rats. 1982 Agents Actions pmid:6299079
Mencia-Huerta JM et al. Is platelet-activating factor (PAF-acether) synthesis by murine peritoneal cells (PC) a two-step process? 1981 Agents Actions pmid:7053072
Vargaftig BB Platelet-activating factor (PAF-acether) 1982 Agents Actions pmid:7164939
Bette P and Bienvenue A Exchange of a spin-labeled analog of PAF-acether between micelles, serum albumin and model membranes. 1982 Agents Actions pmid:7164940
Lartigue-Mattei C et al. Pharmacokinetic study of PAF-acether. Preliminary results after the intravenous administration of a 3H-labelled product to the rabbit. 1982 Agents Actions pmid:7164941
Morgat JL et al. Radio-labelling of 1-O-alkyl, 2-O-acetyl, sn-glycero-3-phosphorylcholine, 1-O-(9,10-di3H)-octadecyl PAF-acether. 1982 Agents Actions pmid:7164942
Convert O et al. 1H NMR of PAF-acether: influence of solvent on its structure. 1982 Agents Actions pmid:7164943
Borrel MC et al. Additional techniques for the total synthesis of PAF-acether. 1982 Agents Actions pmid:7164944
Benveniste J et al. Release of platelet-activating factor (PAF-acether) and 2-lyso PAF-acether from three cell types. 1982 Agents Actions pmid:7164945
Arnoux B et al. Release of PAF-acether from human blood monocytes. 1982 Agents Actions pmid:7164946
Vargaftig BB et al. Platelet-tissue interaction: role of platelet-activating factor (PAF-acether). 1980 Agents Actions pmid:7270336
Heller R et al. S35b, a new phenylsulfonylfuroxan compound, inhibits thrombin-induced synthesis of platelet-activating factor and prostacyclin in human endothelial cells. 1993 Agents Actions pmid:7517616
Louis R et al. Potentiation of histamine release from human leucocytes by PAF. 1994 Agents Actions pmid:7521570
Czarnetzki BM and Benveniste J Effect of synthetic PAF-acether on human neutrophil function. 1981 Agents Actions pmid:7041568
Camussi G et al. Neutropenia induced by platelet-activating factor (PAF-acether) released from neutrophils: the inhibitory effect of prostacyclin (PGI2). 1981 Agents Actions pmid:7041569
de Bernardis E et al. Protective effects of papaverine salicylate in mouse ear dermatitis and PAF-induced rat paw oedema. 1994 Agents Actions pmid:7847181